» Articles » PMID: 38366205

Roles of HOTAIR Long Non-coding RNA in Gliomas and Other CNS Disorders

Overview
Publisher Springer
Date 2024 Feb 17
PMID 38366205
Authors
Affiliations
Soon will be listed here.
Abstract

HOX transcript antisense intergenic RNA (HOTAIR) is a long non-coding RNA (lncRNA) which is increasingly being perceived as a tremendous molecular mediator of brain pathophysiology at multiple levels. Epigenetic regulation of target gene expression carried out by HOTAIR is thorough modulation of chromatin modifiers; histone methyltransferase polycomb repressive complex 2 (PRC2) and histone demethylase lysine-specific demethylase 1 (LSD1). Incidentally, HOTAIR was the first lncRNA shown to elicit sponging of specific microRNA (miRNA or miR) species in a trans-acting manner. It has been extensively studied in various cancers, including gliomas and is regarded as a prominent pro-tumorigenic and pro-oncogenic lncRNA. Indeed, the expression of HOTAIR may serve as glioma grade predictor and prognostic biomarker. The objective of this timely review is not only to outline the multifaceted pathogenic roles of HOTAIR in the development and pathophysiology of gliomas and brain cancers, but also to delineate the research findings implicating it as a critical regulator of overall brain pathophysiology. While the major focus is on neuro-oncology, wherein HOTAIR represents a particularly potent underlying pathogenic player and a suitable therapeutic target, mechanisms underlying the regulatory actions of HOTAIR in neurodegeneration, traumatic, hypoxic and ischemic brain injuries, and neuropsychiatric disorders are also presented.

Citing Articles

HOTAIR Participation in Glycolysis and Glutaminolysis Through Lactate and Glutamate Production in Colorectal Cancer.

Flores-Garcia L, Garcia-Castillo V, Perez-Toledo E, Trujano-Camacho S, Millan-Catalan O, Perez-Yepez E Cells. 2025; 14(5).

PMID: 40072116 PMC: 11898799. DOI: 10.3390/cells14050388.


Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.

Jin P, Bai X IBRO Neurosci Rep. 2025; 18:323-337.

PMID: 40034544 PMC: 11872630. DOI: 10.1016/j.ibneur.2025.01.015.


HOTAIR expression as a biomarker in glioblastoma multiforme: a comprehensive meta-analysis of current evidence.

Bahranian A, Koshki M, Farahmandi F, Eftekharian K, Hemmati S, Sattari M Biomark Med. 2025; 19(4):129-137.

PMID: 39868624 PMC: 11834459. DOI: 10.1080/17520363.2025.2455925.


The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

Bora Yildiz C, Du J, Mohan K, Zimmer-Bensch G, Abdolahi S Epigenomics. 2025; 17(2):125-140.

PMID: 39829063 PMC: 11792803. DOI: 10.1080/17501911.2024.2442297.


HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives.

Nazari M, Babakhanzadeh E, Mollazadeh A, Ahmadzade M, Mohammadi Soleimani E, Hajimaqsoudi E Cancer Cell Int. 2024; 24(1):415.

PMID: 39702144 PMC: 11660992. DOI: 10.1186/s12935-024-03612-x.


References
1.
Pahlevan Kakhki M, Nikravesh A, Shirvani Farsani Z, Sahraian M, Behmanesh M . HOTAIR but not ANRIL long non-coding RNA contributes to the pathogenesis of multiple sclerosis. Immunology. 2017; 153(4):479-487. PMC: 5838425. DOI: 10.1111/imm.12850. View

2.
DiSabato D, Quan N, Godbout J . Neuroinflammation: the devil is in the details. J Neurochem. 2016; 139 Suppl 2:136-153. PMC: 5025335. DOI: 10.1111/jnc.13607. View

3.
Li Y, Ren Y, Wang Y, Tan Y, Wang Q, Cai J . A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep. Theranostics. 2019; 9(16):4608-4623. PMC: 6643429. DOI: 10.7150/thno.35188. View

4.
Zheng H, Baranova K, Song J, Yan L, Biswas S, Chakrabarti S . Overexpression of Long Noncoding RNA HOTAIR Is a Unique Epigenetic Characteristic of Myxopapillary Ependymoma. J Neuropathol Exp Neurol. 2020; 79(11):1193-1202. DOI: 10.1093/jnen/nlaa103. View

5.
Shah U, Alsulimani A, Ahmad F, Mathkor D, Alsaieedi A, Harakeh S . Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. Biotechnol Genet Eng Rev. 2022; 38(2):339-383. DOI: 10.1080/02648725.2022.2108994. View